Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.
By Chris Wack Praxis Precision Medicines said it has entered into an exclusive collaboration and license agreement with Tenacia Biotechnology (Shanghai) Co.,.
Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 3,460,000 shares, a growth of 25.4% from the October 31st total of 2,760,000 shares. Based on an average trading volume of 737,900 shares, the short-interest […]
Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.
Canada Could Be a World Leader in Precision Medicine Cancer Treatments if Governments Remove Barriers to Access goodmenproject.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from goodmenproject.com Daily Mail and Mail on Sunday newspapers.